FDA, industry, and patients are talking, but agreement on how to include patient experiences in oncology product prescribing information remains elusive.
According to a JAMA study, only 8.7% of patients with cancer requested medical interventions and only 11.4% of those were deemed inappropriate.
Endocrine Cancer News
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- CD151—A Striking Marker for Cancer Therapy
- Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
- Addition of Levetiracetam May Improve Survival for Glioblastoma
- VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
- Multigene Cancer-Susceptibility Tests Require New Approaches to Patient Counseling
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System
- Vismodegib Safe, Effective in Twelve-Month Study Update
- Dovitinib Shows Activity in Advanced Endometrial Cancer
- Chromosomal Instability Associated with Improved Outcomes in Breast Cancer
- Malignant Gastric Outlet Obstruction
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|